Loading data for NOVN.SW — first visit, this takes a few seconds.

Novartis AG (NOVN.SW)

Swiss: NOVN.SW · Real-Time Price · USD

130.96

+7.70 (6.25%)

At close: Sep 01, 2026, 5:19 PM

Alert

The price, the headline numbers and the latest news, in one place.

6.25% (1D)

Bid	0
Market Cap	249B
Revenue (ttm)	56.7B
Net Income (ttm)	12.8B
	0.49
	5.36
	24.43
	16.49
P/B (ttm)	7.45
P/S (ttm)	4.39
Earnings Date	Oct 27, 2026

Ask	130.96
Volume	4,912,744
Avg. Volume (20D)	2,483,668
Open	129.02
Previous Close	123.26
Day's Range	127.42 - 132.48
52-Week Range	96.03 - 132.48
Analyst	n/a
Price Target	n/a
Dividends	$3.70 (3.00%)
Ex-Dividend Date	Mar 10, 2026

About NOVN.SW

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Apr 3, 1995

Employees 75,267

Stock Exchange Swiss

Ticker Symbol NOVN.SW

Website https://www.novartis.com

Full Company Profile

Financial Performance

In 2025, Novartis's revenue was 56.67B, an increase of 9.57% compared to the previous year's 51.72B. Earnings were 13.98B, an increase of 17.11%.

Financial numbers in CHF Financial Statements

Earnings Surprise

Novartis has released their quarterly earnings on Jul 20, 2026:

Revenue of $14.95B misses estimates by $0, with 0.78% YoY growth.
EPS of 2.41 exceeds estimates by 0.27, with -0.41% YoY decline.

Next Earnings Release

Novartis AG is scheduled to release its earnings on Oct 27, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

5 days ago · Zacks

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

5 days ago · Zacks

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

1 week ago · Stocktwits

IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push

Soon-Shiong teased a trial pairing Pluvicto’s targeted radiation with an IL-15-based immune treatment.

1 week ago · MarketBeat

VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

1 week ago · Zacks

Sustainable Development ETF (SDG) Touches New 52-Week High

SDG hits a 52-week high as strong earnings from top holdings and institutional ESG inflows fuel momentum, with alpha signaling more gains.

Page 1 of 2

Novartis AG (NOVN.SW)